Novartis Exelon for Alzheimer's NDA filing planned for April, firm tells analysts.
Executive Summary
NOVARTIS EXELON NDA FILING FOR ALZHEIMER's SCHEDULED FOR APRIL, the company indicated during a meeting with financial analysts March 19. The company intends to make "one regulatory submission worldwide during April," with the exception of Japan where Phase II development is ongoing. The company projected that market introductions of the acetylcholinesterase inhibitor would begin in the fourth quarter of 1997.